- Home
- GH vs RITM Comparison
GH vs RITM Comparison
Compare GH & RITM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- RITM
- Stock Information
- Founded
- GH 2011
- RITM 2011
- Country
- GH United States
- RITM United States
- Employees
- GH N/A
- RITM N/A
- Industry
- GH Medical Specialities
- RITM Real Estate Investment Trusts
- Sector
- GH Health Care
- RITM Real Estate
- Exchange
- GH Nasdaq
- RITM Nasdaq
- Market Cap
- GH 5.5B
- RITM 5.8B
- IPO Year
- GH 2018
- RITM N/A
- Fundamental
- Price
- GH $41.72
- RITM $11.24
- Analyst Decision
- GH Strong Buy
- RITM Strong Buy
- Analyst Count
- GH 21
- RITM 10
- Target Price
- GH $52.81
- RITM $13.15
- AVG Volume (30 Days)
- GH 2.7M
- RITM 5.0M
- Earning Date
- GH 04-30-2025
- RITM 04-25-2025
- Dividend Yield
- GH N/A
- RITM 8.90%
- EPS Growth
- GH N/A
- RITM N/A
- EPS
- GH N/A
- RITM 1.19
- Revenue
- GH $773,996,000.00
- RITM $3,560,550,000.00
- Revenue This Year
- GH $19.53
- RITM N/A
- Revenue Next Year
- GH $21.92
- RITM $6.97
- P/E Ratio
- GH N/A
- RITM $9.43
- Revenue Growth
- GH 28.20
- RITM 10.49
- 52 Week Low
- GH $18.01
- RITM $9.13
- 52 Week High
- GH $52.92
- RITM $12.20
- Technical
- Relative Strength Index (RSI)
- GH 43.79
- RITM 57.76
- Support Level
- GH $38.86
- RITM $10.84
- Resistance Level
- GH $52.92
- RITM $11.39
- Average True Range (ATR)
- GH 2.91
- RITM 0.24
- MACD
- GH -0.74
- RITM 0.11
- Stochastic Oscillator
- GH 20.34
- RITM 86.47
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About RITM Rithm Capital Corp.
Rithm Capital Corp operates as a real estate investment trust that provides capital and services to the real estate and financial services industries. The company aims to generate attractive risk-adjusted returns in all interest-rate environments through a complementary portfolio of investments and operating businesses. Its investment portfolio is composed of mortgage servicing-related assets (full and excess MSRs and servicer advances), residential securities (and associated call rights) loans (including single-family rental), and consumer loans. Its operating segments are Origination and Servicing; Investment Portfolio; Residential Transitional Lending; and Asset Management.